Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Talbot

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
British Journal of Cancer|July 20, 2000
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alphaJ P Braybrooke, D J Propper, K J O'Byrne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesisJ P Braybrooke, K J O'Byrne, D J Propper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase CD J Propper, A C McDonald, A Man, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancerN C Levitt, F A Eskens, K J O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
British Journal of Cancer|July 20, 2000
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alphaJ P Braybrooke, D J Propper, K J O'Byrne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesisJ P Braybrooke, K J O'Byrne, D J Propper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase CD J Propper, A C McDonald, A Man, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancerN C Levitt, F A Eskens, K J O'Byrne, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancerB Basu, M G Krebs, R Sundar, et al.
Pageof 7